Kunal C Kadakia1,2, Sally J Trufan3, Megan H Jagosky4, William M Worrilow4, Bradley W Harrison4, Katherine L Broyhill5, Jimmy J Hwang4, Laura W Musselwhite4, Aynur Aktas6, Declan Walsh6, Mohamed E Salem4. 1. Gastrointestinal Medical Oncology, Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, NC, 28204, Charlotte, USA. kunal.kadakia@atriumhealth.org. 2. Department of Supportive Oncology, Levine Cancer Institue, Atrium Health, NC, Charlotte, USA. kunal.kadakia@atriumhealth.org. 3. Department of Cancer Biostatistics, Levine Cancer Institue, Atrium Health, NC, Charlotte, USA. 4. Gastrointestinal Medical Oncology, Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, NC, 28204, Charlotte, USA. 5. Department of Genetics, Levine Cancer Institue, Atrium Health, NC, Charlotte, USA. 6. Department of Supportive Oncology, Levine Cancer Institue, Atrium Health, NC, Charlotte, USA.
Abstract
PURPOSE: Little is known about the use of palliative and hospice care and their impact on healthcare utilization near the end of life (EOL) in early-onset pancreatic cancer (EOPC). METHODS: Patients with EOPC (≤ 50 years) were identified using the institutional tumor registry for years 2011-2018, and demographic, clinical, and rates of referral to palliative and hospice services were obtained retrospectively. Predictors of healthcare utilization, defined as use of ≥ 1 emergency department (ED) visit or hospitalization within 30 days of death, place of death (non-hospital vs. hospital), and time from last chemotherapy administration prior to death, were assessed using descriptive, univariable, and multivariable analyses including chi-square and logistic regression models. RESULTS: A total of 112 patients with EOPC with a median age of 46 years (range, 29-50) were studied. Forty-four percent were female, 28% were Black, and 45% had metastatic disease. Fifty-seven percent received palliative care at a median of 7.8 weeks (range 0-265) following diagnosis. The median time between last chemotherapy and death was 7.9 weeks (range 0-102). Seventy-four percent used hospice services prior to death for a median of 15 days (range 0-241). Rate of healthcare utilization at the EOL was 74% in the overall population. Black race and late use of chemotherapy were independently associated with increase in ED visits/hospitalization and hospital place of death. CONCLUSIONS: Although we observed early referrals to palliative care among patients with newly diagnosed EOPC, short duration of hospice enrollment and rates of healthcare utilization prior to death were substantial.
PURPOSE: Little is known about the use of palliative and hospice care and their impact on healthcare utilization near the end of life (EOL) in early-onset pancreatic cancer (EOPC). METHODS:Patients with EOPC (≤ 50 years) were identified using the institutional tumor registry for years 2011-2018, and demographic, clinical, and rates of referral to palliative and hospice services were obtained retrospectively. Predictors of healthcare utilization, defined as use of ≥ 1 emergency department (ED) visit or hospitalization within 30 days of death, place of death (non-hospital vs. hospital), and time from last chemotherapy administration prior to death, were assessed using descriptive, univariable, and multivariable analyses including chi-square and logistic regression models. RESULTS: A total of 112 patients with EOPC with a median age of 46 years (range, 29-50) were studied. Forty-four percent were female, 28% were Black, and 45% had metastatic disease. Fifty-seven percent received palliative care at a median of 7.8 weeks (range 0-265) following diagnosis. The median time between last chemotherapy and death was 7.9 weeks (range 0-102). Seventy-four percent used hospice services prior to death for a median of 15 days (range 0-241). Rate of healthcare utilization at the EOL was 74% in the overall population. Black race and late use of chemotherapy were independently associated with increase in ED visits/hospitalization and hospital place of death. CONCLUSIONS: Although we observed early referrals to palliative care among patients with newly diagnosed EOPC, short duration of hospice enrollment and rates of healthcare utilization prior to death were substantial.
Authors: Paul A Harris; Robert Taylor; Brenda L Minor; Veida Elliott; Michelle Fernandez; Lindsay O'Neal; Laura McLeod; Giovanni Delacqua; Francesco Delacqua; Jacqueline Kirby; Stephany N Duda Journal: J Biomed Inform Date: 2019-05-09 Impact factor: 6.317
Authors: Michael J Wright; Heidi N Overton; Jonathan A Teinor; Ding Ding; Richard A Burkhart; John L Cameron; Jin He; Christopher L Wolfgang; Matthew J Weiss; Ammar A Javed Journal: J Gastrointest Surg Date: 2019-07-03 Impact factor: 3.452
Authors: Irene J Higginson; Barbara A Daveson; R Sean Morrison; Deokhee Yi; Diane Meier; Melinda Smith; Karen Ryan; Regina McQuillan; Bridget M Johnston; Charles Normand Journal: BMC Geriatr Date: 2017-11-23 Impact factor: 3.921
Authors: Natasha Michael; Greta Beale; Clare O'Callaghan; Adelaide Melia; William DeSilva; Daniel Costa; David Kissane; Jeremy Shapiro; Richard Hiscock Journal: BMC Palliat Care Date: 2019-01-28 Impact factor: 3.234